PD-L1 overexpression on tumour cells strongly correlates with weaker treatment outcomes and adverse prognosis in gastric cancer, hepatocellular carcinoma, renal cell carcinoma, oesophageal cancer, prostate cancer, and ovarian cancer [38]. This evidence concerns the gene CD274 and renal cell carcinoma.